Neovasc Plans ‘Two Shots On Goal’ For Reducer To Treat Angina
Neovasc’ COO Bill Little talked to Medtech Insight about the company’s plans to develop its Reducer transcatheter device to treat cardiac angina associated with or without obstructive coronary disease.
You may also be interested in...
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Jan. 28 through Feb. 4, including announcements from Neovasc, NaturalCycles Nordic, and Elekta.
This week's edition of Medtech Insight's Results Recap, the weekly round-up of major device trial-results, features just one entry - long-term data from a prospective, non-randomized, single-arm anatomic and clinical evaluation of chronic refractory angina patients implanted with Neovasc's Reducer at a single medical center as part of the first-in-human clinical study in 2005. The patients treated in the trial showed sustained improvement in angina class out to 12 years and all seven Reducers implanted in the study were still patent, with no signs of strut fractures, dislocation, thrombosis, or migration.
Results Recap: Neovasc's Coronary Sinus Reducer For Angina; Medtronic's FlorenceM Artificial Pancreas; Spineology's OptiMesh; PHC's Contour Next BGMS
Results Recap is Medtech Insight's exclusive summary of clinical trial results that have been announced or published in the past week, based on information collected by Meddevicetracker. This week's edition covers the week of Sept. 28 - Oct. 4, including trial announcements from Medtronic, Neovasc, OptiMesh, and PHC Holdings.